Cardiovascular Longevity: How to Add Years to Your Heart, and Life to Your Years

Cardiovascular disease is still the leading cause of death worldwide, yet a large share of it is preventable. One idea reframes the whole subject: cardiovascular aging and longevity are two sides of the same coin. The mechanisms that age the arteries are largely the same ones that shorten life, so slowing vascular aging tends to lengthen a healthy life (Pietri and Stefanadis, Journal of the American College of Cardiology 2021). The most important practical consequence is that a great deal of this trajectory is modifiable. The change comes primarily from you: from understanding your own drivers of risk and correcting them, with medical therapy as support rather than substitute.

This guide summarizes what the current evidence supports, from the classic risk factors to the biology of vascular aging, with a clear distinction between what is proven and what is still being tested.

Key takeaways

1. Cardiovascular aging and longevity share the same roots: oxidative stress, chronic low-grade inflammation, insulin resistance, and dyslipidemia.

2. Metabolic health, and insulin sensitivity in particular, is one of the strongest and most modifiable levers you control.

3. LDL cholesterol remains the best-established causal target, while ApoB and a once-in-a-lifetime lipoprotein(a) measurement can refine the picture.

4. Blood pressure and arterial stiffness reflect how fast your vessels are aging, and both respond to early treatment.

5. Lifestyle is the proven foundation; emerging therapies are adjuncts, not shortcuts.
   

   

   
   

Cardiovascular aging and longevity share the same roots

Populations with exceptional longevity, the so-called Blue Zones such as Ikaria in Greece, Sardinia, Okinawa, Nicoya, and Loma Linda, are a natural experiment in slow vascular aging. Studies of these communities point repeatedly to the same favorable pattern: low chronic inflammation, preserved insulin sensitivity, a plant-rich diet, daily physical activity, and freedom from smoking (Pietri and Stefanadis, JACC 2021).

The biology behind this is coherent. Oxidative stress, chronic low-grade inflammation, and disturbed glucose and insulin handling are recognized mechanisms of both atherosclerosis and aging itself. This is why the same habits that lower cardiovascular risk also appear to slow biological aging, and why prevention is best understood not as fighting one number but as keeping these shared mechanisms in balance across decades.

Is cholesterol enough to predict heart risk?

Cholesterol matters most, but it is not the whole story. LDL cholesterol is the most robustly established causal driver of atherosclerotic disease, and lowering it reduces events. What LDL cholesterol measures, however, is the cholesterol carried inside particles, not the number of particles, and it is the particles that lodge in the arterial wall. Two additions can refine the assessment in selected people:

• Apolipoprotein B (ApoB). Every atherogenic particle carries one ApoB molecule, so ApoB estimates the total particle count. It can add information when LDL cholesterol and true risk diverge, which is common with high triglycerides or metabolic changes (Sniderman et al., JAMA Cardiology 2019).

• Lipoprotein(a), or Lp(a). This particle is largely fixed by genetics, stable through life, and independent of lifestyle. Elevated levels raise cardiovascular and aortic valve risk. Because it is essentially constant, measuring it once can uncover an inherited risk that is otherwise invisible (Kronenberg et al., European Heart Journal 2022).

  
  

Blood pressure and arterial stiffness: how fast are your vessels aging?

Blood pressure control is one of the highest-yield interventions in medicine, and the target has become stricter. The 2024 European Society of Cardiology guidelines introduced a category of elevated blood pressure (120 to 139 over 70 to 89 mmHg) and recommend a systolic target of 120 to 129 mmHg for most adults on treatment, based on trials such as SPRINT and STEP.

Behind the numbers is a concept worth understanding: arterial stiffness. Stiffening of the large arteries is the core of what researchers call early vascular aging, and it can be measured through pulse wave velocity. Stiffer arteries independently predict cardiovascular events and mortality. Encouragingly, in the long-lived population of Ikaria, arterial stiffness after age 50 was consistently lower than in the general population, a signature of decelerated vascular aging (Pietri and Stefanadis, JACC 2021). As with cholesterol, the damage accumulates over years, so early and sustained control pays the largest dividend.

Why metabolic health is the central lever

If there is a single hub connecting cardiovascular aging and longevity, it is metabolic health. Insulin resistance, high circulating insulin, and elevated glucose accelerate vascular aging through several converging routes: they drive oxidative stress, promote the formation of advanced glycation end-products that stiffen tissues, and push vascular cells toward premature senescence (Pietri and Stefanadis, JACC 2021). The result is arteries that age faster than the calendar would predict.

The mirror image is just as informative. Preserved insulin sensitivity is a recurring signature of longevity. Members of long-lived families show enhanced insulin sensitivity, and adiponectin, a hormone from fat tissue that improves insulin action and dampens inflammation, is found at higher levels in people past 95 (as reviewed by Pietri and Stefanadis 2021). At the molecular level, the same nutrient-sensing pathways that govern how cells respond to food, including mTOR, AMPK, and the sirtuins, are among the most consistent regulators of lifespan across species, and they are the pathways through which calorie moderation and exercise appear to act. Even metformin, a classic insulin-sensitizing drug, is being studied for possible effects on aging.

For most people this is the most modifiable lever they own. Diet quality, avoiding excess visceral fat, preserving muscle, and staying physically active improve insulin sensitivity directly, often before glucose ever looks abnormal on a standard test. This is also where modern medicine now adds a powerful supportive tool. In the SELECT trial, once-weekly semaglutide, a GLP-1 receptor agonist, reduced major adverse cardiovascular events by 20 percent (from 8.0 to 6.5 percent) in more than 17,000 adults with established cardiovascular disease and overweight or obesity but without diabetes, and the benefit was not explained by glucose lowering alone (Lincoff et al., New England Journal of Medicine 2023). This class is expanding quickly: GLP-1 receptor agonists, and the newer dual GIP and GLP-1 receptor agonists such as tirzepatide, produce substantial weight loss and improved glycemic control, targeting two core metabolic drivers at once. The lesson is not that a drug replaces the work, but that metabolic risk is both dangerous and treatable, and that the foundation remains what you do daily.

Inflammation and "inflammaging"

Chronic, low-grade inflammation is now recognized as a driver of both atherosclerosis and aging, captured by the term inflammaging: a slowly rising inflammatory tone that accompanies the aging process and tracks with age-related disease and shorter life (Pietri and Stefanadis, JACC 2021). High-sensitivity CRP is a simple marker that can flag this residual inflammatory risk when it is not obvious from lipids.

Much of this inflammation has modifiable sources. Visceral fat is an active inflammatory organ, and metabolic dysfunction and inflammation reinforce each other. The most reliable ways to lower inflammatory tone are the familiar ones: a predominantly plant-based, Mediterranean-style diet, regular physical activity, and reducing excess body fat, all of which have measurable anti-inflammatory effects. In other words, the same lifestyle that protects metabolism also cools inflammation.

How much does fitness matter for longevity?

More than most people expect. In a Cleveland Clinic analysis of 122,007 adults, cardiorespiratory fitness was inversely related to long-term mortality with no observed upper limit of benefit, and the least fit had roughly five times the mortality of the fittest, a gap comparable to or greater than that of smoking, diabetes, or hypertension (Mandsager et al., JAMA Network Open 2018). Regular exercise is also associated with a higher probability of reaching age 90 in good functional health (Yates et al., Arch Intern Med 2008, as reviewed by Pietri and Stefanadis 2021).

The benefits are more than the sum of improved risk factors. Physical activity reduces inflammation and oxidative stress, improves the function of the vessel lining, and has even been linked to longer telomeres, one of the cell's markers of biological age.

What about diet?

The Mediterranean dietary pattern has the deepest evidence base, from the classic Seven Countries Study to a large Greek cohort in which closer adherence predicted lower mortality (Trichopoulou et al., New England Journal of Medicine 2003). The PREDIMED trial reported that a Mediterranean diet supplemented with extra-virgin olive oil or nuts lowered major cardiovascular events in high-risk adults. In the interest of full transparency, PREDIMED was retracted and republished in 2018 after randomization irregularities were found, though the reanalysis left the conclusions materially unchanged (Estruch et al., New England Journal of Medicine 2018). Read alongside decades of consistent data, the pattern holds up. Moderate calorie intake, a hallmark of the Okinawan diet, is one of the most reproducible longevity signals in laboratory and population studies (as reviewed by Pietri and Stefanadis 2021). The common thread across Blue Zones is not a single superfood but a sustained, mostly plant-based, calorie-moderate pattern.

Do smoking, sleep, and stress still matter?

They do, and their impact is often underestimated. Even light smoking is not benign: smoking about one cigarette a day carries roughly half the excess risk of coronary heart disease and stroke of smoking twenty, not one twentieth, and there is no safe level (Hackshaw et al., BMJ 2018). The upside is that quitting works: cessation is followed by a clear reduction in cardiovascular risk over the following years (Duncan et al., JAMA 2019, as reviewed by Pietri and Stefanadis 2021). Obstructive sleep apnea and chronic psychosocial stress are further accelerators of vascular disease that frequently go unaddressed.

Can we see heart disease before symptoms?

Yes, and it can change decisions. Blood tests estimate risk, while imaging can document actual disease. Carotid ultrasound is especially useful here: a simple, noninvasive, radiation-free scan that reveals wall thickening or plaque, often years before symptoms. Its value is not theoretical. The PESA study found subclinical atherosclerosis even in people with normal LDL cholesterol and no evident risk factors (Fernández-Friera et al., JACC 2017). Finding disease while it is still silent is precisely the moment when correcting the underlying drivers pays off most.

Biological age, the frontier, and where the real change comes from

Researchers increasingly distinguish biological age from chronological age, using markers such as telomere length and epigenetic (DNA methylation) clocks. These tools are promising for estimating how fast someone is aging, but they are not yet standard for guiding treatment.

The same honesty applies to new drugs. For lipoprotein(a), no medication is yet approved to lower it, though the first cardiovascular outcomes trial of an Lp(a)-lowering agent (pelacarsen, in the Lp(a)HORIZON study of more than 8,000 patients) is expected to report in 2026 and, as of this writing, has not. Whether lowering Lp(a) reduces events is exactly what that trial will test.

Here is the key point, and it holds even for a genetic factor. While targeted therapies are studied, the proven and available path today is to identify your own drivers of risk, lipids and ApoB, an inherited Lp(a), blood pressure, metabolic health, inflammation, fitness, and to correct what can be corrected. Lifestyle change is the foundation with the strongest and broadest evidence; medical therapy is added as support where it is needed. The change comes primarily from you.

What a cardiovascular longevity assessment involves, and when to see a preventive cardiologist

A thorough assessment integrates three layers: an advanced blood profile (lipids and ApoB, a once-in-a-lifetime Lp(a), and metabolic and inflammatory markers), imaging where appropriate such as carotid ultrasound, and functional and lifestyle measures including cardiorespiratory fitness. Which of these make sense is never a fixed checklist; it depends on personal and family history, baseline values, and overall risk.

If you want to understand your own cardiovascular risk in depth and translate it into a concrete, personalized plan, an evaluation with a cardiologist focused on prevention is the right starting point. You can request a preventive cardiology consultation through this website to begin. Your increase in longevity in Florence starts now.

Frequently asked questions

• Can I actually slow cardiovascular aging? To a meaningful degree, yes. The mechanisms that age the arteries, inflammation, insulin resistance, oxidative stress, and rising blood pressure, are substantially modifiable through diet, activity, weight, and not smoking, with medical therapy where indicated.

• Is cholesterol enough to assess heart risk? For many people the standard lipid profile is adequate, but it can underestimate risk when particle number and LDL cholesterol diverge. ApoB and a one-time Lp(a) measurement can refine the picture.

• What is Lp(a), and who should be tested? Lp(a) is a genetically determined, lifelong-stable particle that independently raises cardiovascular risk. Because it is measured once and can reveal hidden inherited risk, current guidance supports measuring it at least once in adulthood.

• Why is insulin sensitivity so important? Insulin resistance accelerates vascular aging even before glucose is abnormal, while preserved insulin sensitivity is a recurring feature of long-lived populations. It is also one of the levers most responsive to diet and exercise.

• Can exercise reduce my risk even if I start later? Yes. Higher cardiorespiratory fitness is linked to lower mortality with no observed ceiling, and gains at any age are associated with benefit.

Take the first step toward cardiovascular longevity: book a preventive cardiology consultation in Florence with Dr. Andrea Bernardini.

This article is for information and general education only and does not replace a personalized medical evaluation. The tests and treatments mentioned must be prescribed and interpreted within a specialist consultation.

Key scientific references

1. Pietri P, Stefanadis C. Cardiovascular aging and longevity: JACC state-of-the-art review. J Am Coll Cardiol. 2021;77(2):189-204.

2. Ference BA, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Consensus statement of the EAS Consensus Panel. Eur Heart J. 2017;38(32):2459-2472.

3. Sniderman AD, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2019;4(12):1287-1295.

4. Kronenberg F, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-3946.

5. McEvoy JW, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024.

6. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.

7. Mandsager K, et al. Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Netw Open. 2018;1(6):e183605.

8. Trichopoulou A, et al. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med. 2003;348(26):2599-2608.

9. Estruch R, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts (retraction and republication). N Engl J Med. 2018;378(25):e34.

10. Hackshaw A, et al. Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies. BMJ. 2018;360:j5855.

11. Duncan MS, et al. Association of smoking cessation with subsequent risk of cardiovascular disease. JAMA. 2019;322(7):642-650.

12. Barzilai N, et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA. 2003;290(15):2030-2040.

13. Fernández-Friera L, et al. Normal LDL-cholesterol levels are associated with subclinical atherosclerosis in the absence of risk factors (PESA study). J Am Coll Cardiol. 2017;70(24):2979-2991.